Business Context and Reporting Period
This Form 8-K is a Current Report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on February 10, 2025, covering events occurring on February 6 and February 7, 2025. The filing details the entry into material definitive agreements for capital raising and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
The filing outlines two concurrent capital raising transactions priced at $2.05 per share:
- Private Placement (PIPE): Sale of 7,536,708 common shares and pre-funded warrants for 3,069,925 shares. Expected gross proceeds: approximately $21.7 million.
- Registered Direct Offering: Sale of 3,609,755 common shares. Expected gross proceeds: approximately $7.4 million.
- Total Expected Gross Proceeds: Approximately $29.1 million before offering expenses.
- Use of Proceeds: General corporate purposes and working capital.
- Prior Sales Activity: Under a terminated Sales Agreement with Needham & Company, LLC, the company sold $1.8 million of common stock prior to termination.
The filing does not provide current revenue, profit, cash flow, margin, or debt figures.
Material Changes and Agreements
- Entry into Material Definitive Agreements: Execution of a PIPE Purchase Agreement and a Registered Direct Purchase Agreement on February 7, 2025. Closing is expected on or about February 10, 2025.
- Termination of Material Definitive Agreement: The company terminated its Sales Agreement with Needham & Company, LLC effective February 8, 2025, following notice given on February 6, 2025.
- Registration Rights: The company agreed to file a registration statement for the resale of PIPE securities by March 31, 2025.
Outlook, Risks, and Management Commentary
Management intends to use the net proceeds for general corporate purposes and working capital. The filing includes standard forward-looking statements regarding the expected closing of the transactions and the exercise of pre-funded warrants. Risks include the possibility that actual results may differ materially from projections due to uncertainties inherent in the evolving environment. The company notes it does not plan to publicly update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting offering expenses.
- Confirm the filing and effectiveness date of the registration statement for the PIPE securities (targeted by March 31, 2025).
- Review the company's most recent 10-K or 10-Q to assess current liquidity and working capital needs relative to the $29.1 million raised.
- Monitor the exercise of pre-funded warrants and the resulting dilution impact on existing shareholders.
- Check for any subsequent filings regarding the utilization of proceeds.